American biotech company Moderna is going to set the price for a course of vaccine from COVID-19 at the level of 50-60 dollars, reports Financial Times, citing informed sources.
As noted, a similar price, the company will establish for the United States and other countries with “high income”.
According to the newspaper, the price is likely to change as Moderna rated their preparation higher than Pfizer and BioNTech to enter into an agreement with U.S. authorities to sell up to 600 million doses of the newly invented vaccine against coronavirus infection at a cost of 19.5 per dose. According to one of the newspaper’s sources requested Moderna value “causes significant difficulties in the negotiations”, as other manufacturers have promised much lower prices.
Earlier it was reported that the American biotech company Moderna the start of the third stage of clinical trials of vaccines against coronavirus. Project vaccine, the company received the support of the Federal government of the United States, sending about $ 500 million and selected it as one of the first to start large scale human trials.
According to the latest data, worldwide identified 16 481 230 cases of infection with coronavirus, 9 572 619 recovered, 654 052 died.
Read also: “Onishchenko is sure that Russia will not be a second wave of coronavirus”
